<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578171</url>
  </required_header>
  <id_info>
    <org_study_id>CÉR21903</org_study_id>
    <nct_id>NCT04578171</nct_id>
  </id_info>
  <brief_title>Residual Exacerbations With Mepolizumab</brief_title>
  <official_title>Type and Mechanisms of Residual Asthma Exacerbations in Patients Treated With Mepolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a two-year prospective study to characterize the nature of the remaining asthma&#xD;
      exacerbations in patients treated with mepolizumab. Participants will be assessed every six&#xD;
      months from pre- until two years of treatment in addition to whenever they experience an&#xD;
      exacerbation of asthma during the study period. During these visits, various clinical,&#xD;
      physiological and inflammatory outcomes will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before initiation of mepolizumab, a recording of patient's demographics, clinical,&#xD;
      physiological and inflammatory features will be recorded. All subjects will be reassessed for&#xD;
      the above measures at 6, 12, 18 and 24 months.&#xD;
&#xD;
      In addition to the above visits, patients will be assessed every time they experience either&#xD;
      moderate or severe exacerbation of asthma over the treatment period.&#xD;
&#xD;
      Based on the percentage of sputum eosinophils and neutrophils, the type of inflammatory&#xD;
      exacerbation will be determined&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eosinophilic vs non-eosinophilic remaining exacerbation during the treatment period</measure>
    <time_frame>Between baseline and month 24</time_frame>
    <description>Eosinophilic exacerbation defined as &gt;=3% sputum eosinophils. Ratio of eosinophilic vs non eosinophilic asthma exacerbation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in asthma control on the Asthma Control Questionnaire (ACQ-5) at 24 months</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>The ACQ-5 is a validated, self-reported questionnaire assessing asthma control over the last week. Possible scores range from 0 (complete control) to 5 (no control). Change = (Month 24 score - baseline score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in post-bronchodilator forced expiratory volume in one second (FEV1) at 24 months</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Value of FEV1 measured after inhalation of 400ug of salbutamol. Recorded in Li. (Month 24 FEV1 value - baseline FEV1 value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in post-bronchodilator FEV1/forced vital capacity (FVC) ratio at 24 months</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Value of FEV1/FVC measured after inhalation of 400 ug of salbutamol. (Month 24 value - baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fraction of exhaled nitric oxide (FeNO) levels at 24 months</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Recorded in ppb using the mean of two reproducible measurements. (Month 24 value - baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percentage of sputum eosinophils at 24 months</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Determined from induced sputum analysis. (Month 24 sputum eosinophil percentages - baseline sputum eosinophil percentages)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percentage of sputum neutrophils</measure>
    <time_frame>Baseline and month 24</time_frame>
    <description>Determined from induced sputum analysis. (Month 24 sputum neutrophil percentages - baseline sputum neutrophil percentages).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Subjects with severe asthma treated with mepolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>100 mg subcutaneous injections every four weeks</description>
    <arm_group_label>Study population</arm_group_label>
    <other_name>nucala</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe asthma treated with mepolizumab at the IUCPQ-UL a tertiary care center&#xD;
        from the Quebec city area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society&#xD;
&#xD;
          -  Eligible for mepolizumab treatment&#xD;
&#xD;
          -  Able and willing to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any respiratory disease apart from asthma&#xD;
&#xD;
          -  Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA)&#xD;
             or hypereosinophilic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andréanne Côté, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCPQ-UL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Eve Boulay, MSc</last_name>
    <phone>4186568711</phone>
    <phone_ext>2617</phone_ext>
    <email>marie-eve.boulay@criucpq.ulaval.ca</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Andréanne Côté</investigator_full_name>
    <investigator_title>Respirologist-intensivist</investigator_title>
  </responsible_party>
  <keyword>exacerbation</keyword>
  <keyword>inflammation</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

